age1 is a venture capital firm catalyzing the next generation of founder-led longevity biotech companies. Launched from The Longevity Fund, it invests in contrarian founders building therapeutics, tools, and technologies targeting aging and age-related disease.
40% of their portfolio is in Mobility & Transportation. They made 4 investments in the last 12 months. Their most common stage is seed (40% of deals). Average disclosed round size is $53.6M (across 5 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Seed
Last 12 Mo
4
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Loyal | Series C | $100M | Feb 2026 |
 Aerska | Series A | $39M | Feb 2026 |
 Skeletalis | Seed | $8M | Nov 2025 |
| Aerska | Seed | $21M | Oct 2025 |
 Loyal | Unknown | $100M | — |
Top Co-Investors
Baillie Gifford2 shared
EQT Life Sciences1 shared
Larsen Ventures1 shared
Diaspora Ventures1 shared
Norrsken VC1 shared
Speedinvest1 shared
Exor Ventures1 shared
Backed VC1 shared
PsyMed Ventures1 shared
BlueYard Capital1 shared
Adara Ventures1 shared
Pillar VC1 shared
University of Michigan1 shared
The Longevity Fund1 shared
BoxGroup1 shared
Last updated: 7 September 2026